The Long Record · Octo Health with Catarina Costa, MD
Your cholesterol came back normal. That is not the same as safe.
It is one of the most common things people hear after a lipid panel. Everything is fine. And it feels like an answer. But the standard lipid panel was built around what was measurable in the 1960s, and the trials that shaped treatment guidelines were designed around those same numbers. The vocabulary persisted. The biology moved on.
Particles, not cholesterol
Atherosclerosis is not caused by cholesterol in the blood. It is caused by lipoprotein particles crossing the arterial wall and being retained there. Each atherogenic particle, whether LDL, VLDL, IDL, or Lp(a), carries exactly one apolipoprotein B molecule on its surface. This is structural, not statistical.
ApoB is therefore a direct count of the particles capable of entering the artery wall. LDL-C measures only the cholesterol those particles happen to carry, which varies with particle size and density. Two patients with identical LDL-C can carry a very different particle burden: the same cholesterol distributed across 80 large particles or 200 small, dense ones. The cholesterol reading is identical. The exposure is not.[1]
LDL-C tells you how much cholesterol is being carried. ApoB tells you how many vehicles are doing the carrying.
The mechanism is mechanical
Small, dense LDL particles penetrate the endothelium more readily, are retained longer, and are more susceptible to oxidation. Oxidized LDL triggers the macrophage response that initiates plaque. ApoB counts the vehicles doing the lodging. It indexes what is happening in the arterial wall more directly than any cholesterol concentration.[2]
The clinical consequence of ignoring this is discordance: a patient who has a cardiac event despite a normal LDL-C often carries an elevated ApoB. Treating to an LDL-C target while ApoB stays high leaves the actual driver unaddressed.[3]
The evidence is causal, not associative
Mendelian randomization studies use inherited genetic variants to remove confounding, approximating a lifelong randomized trial. They consistently show a causal, dose-dependent relationship between ApoB and cardiovascular events, independent of LDL-C.[4]
The 2019 ESC/EAS guidelines keep LDL-C as the primary measure and name ApoB as the preferred alternative for risk assessment in specific groups, including people with high triglycerides, diabetes, obesity or very low LDL-C.[5] This is not a fringe position. It is where the evidence has landed.
See your own cardiac markers, on one timeline.
Octo unifies your labs, records and notes so the numbers are readable visit after visit, not just after the one visit you can find.
The part a single reading cannot show
Atherosclerosis is an integral, not a moment. Plaque accumulates as a function of particle concentration multiplied by time of exposure. The relevant quantity is closer to ApoB-years than to any single ApoB value, in the same way smoking risk is measured in pack-years rather than cigarettes on a given afternoon.[6]
A reading today tells you the rate. Only a series tells you the accumulated dose, the direction, and the velocity. Two people at the same ApoB number are not at the same risk if one has been climbing for a decade and the other has been flat.
The label is a snapshot. Your cardiovascular risk is the line over time.
Why the rest of the cardiac panel earns its place
Lp(a) is largely genetically fixed and worth establishing once, because it shifts the baseline the modifiable markers move around. Lp-PLA2 reports vascular-specific inflammation. hsCRP reports the systemic kind. Non-HDL cholesterol and the triglyceride to HDL ratio add metabolic context.[5]
None of these is a verdict. Each is a line on a chart that only becomes informative when there are enough points to read a slope.
What to do with this
Ask for your ApoB the next time you have a lipid panel ordered. It is not a specialist test. It is available at every major lab. If your doctor has not offered it, ask anyway.
And track it over time. A single reading tells you the rate. The series tells you the direction.
Normal said your cholesterol was fine. ApoB said how many particles were in the wall.
Healthcare stores data. Octo gives it memory.
Walk into your next appointment with everything.
One place for every result, note, test and symptom. Yours.
For educational purposes only. This article presents published clinical research to help you have a more informed conversation with your physician. It is not medical advice, a diagnosis, or a treatment recommendation. Always consult a licensed healthcare provider.
References (Vancouver)
Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011;4(3):337-345.
Tabas I, Williams KJ, Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis. Circulation. 2007;116(16):1832-1844.
Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins. JAMA. 2012;307(12):1302-1309.
Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Eur Heart J. 2017;38(32):2459-2472.
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111-188.
Pencina MJ, Navar AM, Wojdyla D, et al. Quantifying importance of major risk factors for coronary heart disease. Circulation. 2019;139(13):1603-1611.
